Sticker shock

See allHide authors and affiliations

Science  23 Mar 2018:
Vol. 359, Issue 6382, pp. 1348-1349
DOI: 10.1126/science.359.6382.1348

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Physician Peter Bach at Memorial Sloan Kettering Cancer Center is appalled at the sky-high price of cancer treatments in the United States, and he is watching new immune therapies drive them higher still. Checkpoint inhibitors for various solid tumors cost about $150,000 a year, and a personalized treatment called chimeric antigen receptor–T cell therapy tops out at $475,000. Dozens more immunotherapies are in clinical trials, as companies race to reap the monetary rewards. For the past decade, Bach has immersed himself in health policy and economics to decipher and publicize what's driving these high prices. Science spoke with Bach last month.